相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Liewei Wang et al.
CANCER RESEARCH (2010)
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors
Philip Lazarus et al.
DRUG METABOLISM REVIEWS (2010)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer
Hiroko Yamashita et al.
CANCER SCIENCE (2009)
Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
Daniele Generali et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole
William R. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Predicting response and resistance to endocrine therapy: Profiling patients on aromatase inhibitors
William R. Miller et al.
CANCER (2008)
Rational Management of Endocrine Resistance in Breast Cancer A Comprehensive Review of Estrogen Receptor Biology, Treatment Options, and Future Directions
Sara A. Hurvitz et al.
CANCER (2008)
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor
Selma Masri et al.
CANCER RESEARCH (2008)
Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer
J. Michael Dixon
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
William R. Miller et al.
ONCOLOGIST (2008)
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
James N. Ingle
BREAST CANCER RESEARCH (2008)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole
William R. Miller et al.
PHARMACOGENETICS AND GENOMICS (2007)
Aromatase inhibitors - Gene discovery
William R. Miller et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer
Stephen R. D. Johnston et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Neoadjuvant use of endocrine therapy in breast cancer
E. Jane Macaskill et al.
BREAST JOURNAL (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Molecular response to aromatase inhibitor treatment in primary breast cancer
Alan Mackay et al.
BREAST CANCER RESEARCH (2007)
Short-term presurgical treatment for all?
Mitch Dowsett et al.
BREAST CANCER RESEARCH (2007)
Neoadjuvant endocrine therapy for locally advanced breast cancer
Cynthia X. Ma et al.
SEMINARS IN ONCOLOGY (2006)
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: a meta-analysis
Walter Jonat et al.
LANCET ONCOLOGY (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Marc Buyse et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
M Dowsett et al.
ANNALS OF ONCOLOGY (2006)
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole
WR Miller et al.
BRITISH JOURNAL OF CANCER (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience
WR Miller et al.
ENDOCRINE-RELATED CANCER (2005)
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
M Dowsett et al.
ENDOCRINE-RELATED CANCER (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
Y Tao et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
SRD Johnston et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas
P Lal et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biological rationale for endocrine therapy in breast cancer
WR Miller
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Fulvestrant and the sequential endocrine cascade for advanced breast cancer
S Johnston
BRITISH JOURNAL OF CANCER (2004)
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial
L Zhu et al.
CLINICAL CANCER RESEARCH (2004)
Prevention strategies with aromatase inhibitors
PE Goss et al.
CLINICAL CANCER RESEARCH (2004)
Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
LA Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen
WR Miller et al.
EUROPEAN JOURNAL OF CANCER (2003)
Aromatase inhibitors for breast cancer: Lessons from the laboratory
SRD Johnston et al.
NATURE REVIEWS CANCER (2003)
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation
CMW Chan et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2002)
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer
TJ Anderson et al.
BRITISH JOURNAL OF CANCER (2002)
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy
WR Miller et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2001)
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women:: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial
M Baum et al.
BRITISH JOURNAL OF CANCER (2001)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
分享论文
